A Starpharma Holdings Limited (ASX:SPL) product has significantly outperformed a major cancer drug in anti-tumour activity and increased survival in human colon cancer.
The medical company’s outperforming drug, DEP irinotecan is its dendrimer version of the major cancer drug, Camptosar (irinotecan).
In Starpharma’s studies a single treatment administrated on days 1, 8 and 15 showed better results on all cancer models tests, when compared to irinotecan.
Meantime, on its colon cancer models, Starpharma’s product resulted in complete tumor regression and 100 per cent survival.
On the back of the stellar result, Starpharma says it will be expediting its development and scaling up the drug for further pre-clinical studies, prior to clinical trials.
Shares in Starpharma Holdings Limited (ASX:SPL) are trading 2.94 per cent higher to 70 cents.